
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/8151/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:10:33 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--8151 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--8151 block--content--website-notice-block block--content--website-notice-block--8151 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--8151 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--8151 block--content--system-main-block block--content--system-main-block--8151 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--8151 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="field ixbrl-link">
    <a href="ixbrl-viewer"></a>
  </div>
  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001157523-21-000429.rtf%3b%20filename_%3dUTF-8%27%270001157523-21-000429.rtf" type="application/rtf" title="0001157523-21-000429.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001157523-21-000429.pdf%3b%20filename_%3dUTF-8%27%270001157523-21-000429.pdf" type="application/pdf" title="0001157523-21-000429.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001157523-21-000429.xls%3b%20filename_%3dUTF-8%27%270001157523-21-000429.xls" type="application/vnd.ms-excel" title="0001157523-21-000429.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001157523-21-000429.html" type="application/octet-stream" title="0001157523-21-000429-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srrk="http://scholarrock.com/20210406" xmlns="../../../www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_6a38e8e0679c4f878545f82646c44ef5" contextRef="c20210406to20210406" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_dbbf6f1e8bca40aa9a67fd01ad6cbb09" contextRef="c20210406to20210406">0001727196</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="#srrk-20210406.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20210406to20210406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-06</xbrli:startDate><xbrli:endDate>2021-04-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div>
      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">UNITED




          STATES</span><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          SECURITIES AND EXCHANGE COMMISSION</span><br />
        <span style="font-weight: bold;">Washington, D.C. 20549</span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">FORM




          <ix:nonNumeric name="dei:DocumentType" id="Fact_09f893ac65b64bd2af919812d86dc10f" contextRef="c20210406to20210406">8-K</ix:nonNumeric></span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">CURRENT REPORT<br />
      </div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div>&#160;</div>

      <div style="text-align: center;">Date of Report (Date of earliest event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_64826db5d9994bcdb0f91e3d42e185ff" contextRef="c20210406to20210406" format="ixt:datemonthdayyearen">April 6, 2021</ix:nonNumeric></div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_cdf22c7e9e9e4a5b98583a7a4a92178a" contextRef="c20210406to20210406">Scholar Rock Holding Corp</ix:nonNumeric>oration</span><br />
        (Exact Name of Registrant as Specified in Charter)</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" id="z107cf8ce03914b7f865c0dfc5f27fdba" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_133f6767a4334c3493656a9acf99f21b" contextRef="c20210406to20210406" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_95b56c66f72448a9a4b024dcb0f7375c" contextRef="c20210406to20210406">001-38501</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_530618c7a58c41f2bc8c7db5a7706a40" contextRef="c20210406to20210406">82-3750435</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(I.R.S. Employer Identification Number)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: center;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> <br />
        </div>

        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_47f18055a2a54e42bd6bd3f4d9bf3fc1" contextRef="c20210406to20210406">301 Binney Street</ix:nonNumeric><span style="font-weight: bold;">, </span><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_c0bd34f7c759431d823d593ed9f6760f" contextRef="c20210406to20210406">3rd Floor</ix:nonNumeric><span style="font-weight: bold;">, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_80d4ab5dc642408ea1c3d363d544bb33" contextRef="c20210406to20210406">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_065e36a834994ad893301f7d28fa6d04" contextRef="c20210406to20210406">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_8961f65906104ab18091b90185b3c1fc" contextRef="c20210406to20210406">02142</ix:nonNumeric></span></div>

        (Address of Principal Executive Offices) (Zip Code)</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_ea4a5ac3f0354070b74903b2fb1e00d6" contextRef="c20210406to20210406">857</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_1c6cd6dfe0484ac489a528cb833ecc83" contextRef="c20210406to20210406">259-3860</ix:nonNumeric></span><br />
        (Registrant&#8217;s telephone number, including area code)</div>

      <div style="text-align: center;"> <br />
      </div>

      <div style="text-align: center;">(Former name or former address, if changed since last report)</div>

      <div>&#160;</div>

      <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

      <div>&#160;</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_52f6e2889ea94cedb0a8159a3a627079" contextRef="c20210406to20210406" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Written





        communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_62a24276469d467c9a2d7695d3efe004" contextRef="c20210406to20210406" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Soliciting





        material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_6526f82ce8d348818105809a884b346b" contextRef="c20210406to20210406" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement





        communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_eb644e9521f7462c80a2bcdcb8ba837a" contextRef="c20210406to20210406" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement





        communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

      <div>&#160;</div>

      <div>Securities registered pursuant to Section 12(b) of the Act:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" id="z70d7d1ffb9404515954838ce95d0dafe" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Trading Symbol(s)</div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_6746e1df272d45149f13609973c0f4a7" contextRef="c20210406to20210406">Common Stock, par value $0.001 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_79668de9e0554c8faef76ac262f469ea" contextRef="c20210406to20210406">SRRK</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_daa64774cac54424ba60cc92a568b361" contextRef="c20210406to20210406" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div>&#160;</div>

      <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company
        <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_150aeedcaf754a0892d450adefbeecdf" contextRef="c20210406to20210406" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div>&#160;</div>

      <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
        Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" id="Fact_ff8bee4323f64a47861c7acc5c276969" contextRef="c20210406to20210406" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div>&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div style="font-weight: bold;"> <br />
      </div>

      <div style="font-weight: normal;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze4aa713e0baa435a8a46b59abb4be27c">


  <tr>

    <td style="width: 6%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.01.</div>
              </td>

    <td style="width: 94%; vertical-align: middle;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Regulation FD Disclosure.</div>
              </td>

  </tr>


</table>
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On April 6, 2021, Scholar Rock Holding Corporation (the &#8220;Company&#8221;) issued a press release announcing positive 12-month top-line results
          from the TOPAZ Phase 2 clinical trial evaluating apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy. A copy of the press release is attached hereto as Exhibit 99.1.</div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information in this Item 7.01 of Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of
          Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the
          Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.</div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z766067b91cb642e5920bcf6ca494ef50">


  <tr>

    <td style="width: 6%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 8.01.</div>
              </td>

    <td style="width: 94%; vertical-align: middle;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Other Events.</div>
              </td>

  </tr>


</table>
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company will host a conference call and audio webcast at 8:00 am ET on Tuesday, April 6, 2021 to discuss the top-line results from
          the apitegromab TOPAZ Phase 2 clinical trial. A copy of the presentation slides to be used by the Company during the conference call and webcast is attached hereto as Exhibit 99.2 and is incorporated herein by reference. A live webcast of the
          conference call may be accessed by visiting the Investors &amp; Media section of the Company&#8217;s website at http://investors.scholarrock.com.</div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zace6e924c0204566a9fe1a795f08fa84">


  <tr>

    <td style="width: 6%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01.</div>
              </td>

    <td style="width: 94%; vertical-align: middle;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
              </td>

  </tr>


</table>
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits:</div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z845d15dcc57e46499e3e334e9e67e93a">


  <tr>

    <td style="width: 6%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br />
                  </span>No.</div>
              </td>

    <td style="width: 2%; vertical-align: bottom;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 92%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: middle;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 2%; vertical-align: middle;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 92%; vertical-align: middle;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; white-space: nowrap;">
                <div><a href="#a52406941ex99_1.htm">99.1</a></div>
              </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
                <div>&#160;</div>
              </td>

    <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
                <div><a href="#a52406941ex99_1.htm">Press Release issued by Scholar Rock Holding Corporation, dated April 6, 2021</a></div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: middle; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
                <div>&#160;</div>
              </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
                <div>&#160;</div>
              </td>

    <td style="width: 92%; vertical-align: middle; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
                <div>&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; white-space: nowrap;">
                <div><a href="#a52406941ex99_2.htm">99.2</a></div>
              </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
                <div>&#160;</div>
              </td>

    <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
                <div><a href="#a52406941ex99_2.htm">Presentation Slide Deck</a></div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: middle;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 2%; vertical-align: middle;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 92%; vertical-align: middle;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
              </td>

    <td style="width: 2%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 92%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        </div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

        <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the&#160;Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
          by the undersigned hereunto duly authorized.</div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zda29f2c285dc47138a07bacc8d56eb42">


  <tr>

    <td style="width: 50.06%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="2" style="width: 49.94%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Scholar Rock Holding Corporation</div>
              </td>

  </tr>

  <tr>

    <td style="width: 50.06%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 3.1%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 46.84%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 50.06%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: April 6, 2021</div>
              </td>

    <td style="width: 3.1%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
              </td>

    <td style="width: 46.84%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">/s/ Junlin Ho</span></div>
              </td>

  </tr>

  <tr>

    <td style="width: 50.06%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 3.1%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 46.84%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Junlin Ho</div>
              </td>

  </tr>

  <tr>

    <td style="width: 50.06%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 3.1%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 46.84%; vertical-align: top;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">General Counsel and Corporate Secretary</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

      </div>

      <br />
    </div>

  </div>

</body>

<!-- Mirrored from investors.scholarrock.com/node/8151/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:10:33 GMT -->
</html>
</XBRL>
<div><a name="a52406941ex99_1.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div><br>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal
          Muscular Atrophy (SMA)</b> </h1>
      <div class="bw-release-subhead">
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Data further demonstrate proof-of-concept for the therapeutic potential of apitegromab in patients with Type 2 and Type 3 SMA</i> </b></p>
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Phase 3 registrational trial initiation expected by the end of 2021 </i> </b></p>
        <p style="text-align: center; list-style-position: inside;"><b> - <i>European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to apitegromab, recognizing unmet medical needs of patients with SMA </i> </b></p>
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Scholar Rock to host webcast today at 8:00am ET</i> </b></p>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 6, 2021--Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced
            positive top-line data from the TOPAZ Phase 2 clinical trial evaluating apitegromab (SRK-015) in patients with Type 2 and Type 3 spinal muscular atrophy (SMA). </p>
          <p> &#8220;These top-line 12-month data provide further support towards establishing apitegromab as a potential first muscle-directed therapy for patients with SMA,&#8221; said Yung Chyung, M.D., Chief Medical Officer of Scholar Rock. &#8220;The findings also
            offer important insights into myostatin biology and our scientific approach of targeting the latent forms of growth factors. We look forward to advancing the development and investigation of apitegromab as we plan to initiate a pivotal trial in
            SMA by the end of 2021 and explore its potential in additional disease areas.&#8221; </p>
          <p> <b><u>Key findings from the 12-month top-line analysis include:</u></b> </p>
          <ul style="list-style-type: disc;">
            <li> <b>Cohort 1:</b> 5-21 years of age, ambulatory Type 3, 20 mg/kg dose monotherapy and in conjunction with nusinersen:
              <ul style="list-style-type: circle;">
                <li> Observed a mean change from baseline in Revised Hammersmith Scale (RHS) of a 0.3-point decline. </li>
                <li> Majority of patients across the cohort (57%, 13/23 of patients) maintained or improved their motor function, as reflected by a <u>&gt;</u>0-point change from baseline in RHS score, and 22% of patients (5/23)
                  attained a <u>&gt;</u>3-point increase from baseline. </li>
                <li> Results suggest potential clinical effect in certain patients in this population. </li>
              </ul>
            </li>
            <li> <b>Cohort 2:</b> 5-21 years of age, Type 2 and non-ambulatory Type 3 who initiated nusinersen &#8805;5 years old, 20 mg/kg dose:
              <ul style="list-style-type: circle;">
                <li> Observed a mean change from baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) of a 0.6-point improvement. </li>
                <li> Majority of patients (64%, 9/14 of patients) attained a <u>&gt;</u>1-point increase from baseline and 29% of patients (4/14) attained a <u>&gt;</u>3-point increase from baseline. </li>
                <li> Results support the potential durability of the improvements in motor function observed at the six-month interim analysis. </li>
              </ul>
            </li>
            <li> <b>Cohort 3:</b> &#8805;2 years of age, Type 2 who initiated nusinersen &lt;5 years of age:
              <ul style="list-style-type: circle;">
                <li> Observed a mean change from baseline in HFMSE of 7.1-point and 5.3-point improvements in the 20 mg/kg dose and the 2 mg/kg dose arms, respectively. </li>
                <li> Across the full cohort, 59% of patients (10/17) attained a <u>&gt;</u>5-point increase and 35% of patients (6/17) attained a &gt;10-point increase from baseline. </li>
                <li> Results demonstrate further improvements in motor function beyond what had been observed at the six-month interim analysis. </li>
                <li> Dose response continued to be observed based upon clinical efficacy (HFMSE improvements) and pharmacodynamics (target engagement). </li>
              </ul>
            </li>
            <li> No safety signals for apitegromab were identified as of the 12-month top-line analysis. The five most frequently reported treatment-emergent adverse events (TEAEs) were headache, pyrexia, upper respiratory tract infection, cough, and
              nasopharyngitis. </li>
            <li> All 57 patients who completed the 12-month TOPAZ trial have opted into the extension period. </li>
          </ul>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> &#8220;These 12-month results from the Phase 2 apitegromab TOPAZ trial have built upon the previously announced exciting 6-month interim results,&#8221; said Thomas Crawford, M.D., Professor of Neurology at the Johns Hopkins School of Medicine and Lead
            Investigator of the TOPAZ trial. &#8220;There looks to be promising potential for a muscle-directed therapy that will complement the unmet need still evident, and likely emerging, in many individuals with SMA who receive SMN-enhancing therapies.
            Though much work remains to be done, I believe the results are wonderful news for the SMA community, and I am enthusiastic about the potential that apitegromab may offer for further meaningful functional improvements.&#8221; </p>
          <p> <strong><i><u>Detailed summary of the TOPAZ 12-month top-line results by cohort <br>
                  </u></i></strong>Apitegromab is a selective inhibitor of the activation of latent myostatin. The TOPAZ Phase 2 proof-of-concept trial enrolled 58 patients with Type 2 and Type 3 SMA across 16 study sites in the United States and
            Europe. The trial evaluated the safety and efficacy of intravenous apitegromab dosed every four weeks (Q4W) over a 12-month treatment period. Four patients (one in Cohort 2 and three in Cohort 3) each missed three consecutive doses of
            apitegromab over the course of the 12-month treatment period due to COVID-19-related site access restrictions and are excluded from the prespecified intent-to-treat primary analysis. </p>
          <p> <strong>Cohort 1: <font style="text-align: center; list-style-position: inside;font-weight:normal;">This open-label, single-arm cohort enrolled 23 patients with ambulatory Type 3 SMA. Patients were treated with 20 mg/kg of apitegromab
                either as a monotherapy or in conjunction with an approved SMN upregulator therapy (nusinersen).</font> </strong>The primary objectives of Cohort 1 were to assess safety and the mean change from baseline in RHS following 12 months of
            treatment. </p>
          <p> In Cohort 1 (pooled population), the mean change from baseline in RHS score was a 0.3-point decline. The <strong><font style="text-align: center; list-style-position: inside;font-weight:normal;">Cohort 1 efficacy data suggest a potential
                clinical effect of apitegromab in certain patients in this population, as 57% of patients observed a maintenance or improvement in RHS score (&gt;0-point change from baseline) and 22% of patients achieved at least a 3-point increase in RHS
                score from baseline.</font></strong> </p>
          <table cellspacing="0" id="z6a8914af9389437890474edcea10976c" style="margin-bottom: 10px;margin-left: 0px; margin-right: auto; font-size: 10pt;">

              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> <b>Cohort 1 <br>
                    </b>(Intent-to-treat population) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>Apitegromab 20 mg/kg <br>
                      monotherapy (n=11)</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>Apitegromab 20 mg/kg <br>
                      + nusinersen (n=12)</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>Apitegromab pooled <br>
                      (n=23)</b> </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> Mean change from baseline in RHS score (95% CI) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> -0.4 (-3.9, +3.1) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> -0.3 (-2.0, +1.4) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> -0.3 (-2.1, +1.4) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> % of patients attaining &#8805;0-point increase in RHS score </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 6/11 (55%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 7/12 (58%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 13/23 (57%) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> % of patients attaining &#8805;1-point increase in RHS score </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 4/11 (36%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 5/12 (42%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 9/23 (39%) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> % of patients attaining &#8805;3-point increase in RHS score </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 3/11 (27%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 2/12 (17%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 5/23 (22%) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> % of patients attaining &#8805;5-point increase in RHS score </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 1/11 (9%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 0/12 (0%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 1/23 (4%) </p>
                </td>
              </tr>

          </table>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <strong>Cohort 2: <font style="text-align: center; list-style-position: inside;font-weight:normal;">This open-label, single-arm cohort enrolled 15 patients with Type 2 or non-ambulatory Type 3 SMA and who were already receiving treatment
                with an approved SMN upregulator (nusinersen) initiated at age five years or older.</font> </strong>One patient missed three consecutive doses of apitegromab due to COVID-19-related site access restrictions and was excluded from the
            prespecified intent-to-treat primary analysis. The primary objectives of the cohort were to assess safety and the mean change from baseline in HFMSE following 12 months of treatment. </p>
          <p> <strong><font style="text-align: center; list-style-position: inside;font-weight:normal;">Cohort 2 efficacy data demonstrate improvement of motor function from baseline. The mean change from baseline in HFMSE score was a 0.6-point increase.
                The majority (64%) of patients achieved at least a 1-point increase in HFMSE and 29% of patients achieved at least a 3-point increase in HFMSE from baseline. Potential durability of effect was observed up to 12 months of treatment. </font></strong>
          </p>
          <p> <strong><font style="text-align: center; list-style-position: inside;font-weight:normal;">One patient in Cohort 2 was identified as having received concomitant treatment with an acetylcholinesterase inhibitor before and during the study,
                which was not permitted by the trial protocol. This patient experienced a 7-point decline in HFMSE score at the 12-month timepoint. In the per protocol analysis conducted in accordance with the prespecified approach, which excludes this
                patient as well as the patient who missed three consecutive doses due to COVID-19-related site access restrictions, the mean change from baseline in HFMSE score for Cohort 2 was a 1.2-point improvement. </font></strong> </p>
          <table cellspacing="0" id="z6ac1194515e341599203781756064e95" style="margin-bottom: 10px;margin-left: 0px; margin-right: auto; font-size: 10pt;">

              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> <b>Cohort 2 </b> </p>
                </td>
                <td rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;" colspan="2">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>Apitegromab 20 mg/kg + nusinersen </b> </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>Intent-to-treat (n=14)</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>Per Protocol (n=13)</b> </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> Mean change from baseline in HFMSE score (95% CI) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> +0.6 (-1.4, +2.7) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> +1.2 (-0.5, 2.9) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> % of patients attaining &#8805;1 point increase in HFMSE score </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 9/14 (64%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 9/13 (69%) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> % of patients attaining &#8805;3 point increase in HFMSE score </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 4/14 (29%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 4/13 (31%) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> % of patients attaining &#8805;5 point increase in HFMSE score </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 2/14 (14%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 2/13 (15%) </p>
                </td>
              </tr>

          </table>
          <p> <strong>Cohort 3: <font style="text-align: center; list-style-position: inside;font-weight:normal;">This randomized, double-blind, parallel arm portion of the trial enrolled patients with Type 2 SMA who had initiated treatment with an
                approved SMN upregulator (nusinersen) before five years of age. Twenty patients were randomized in a 1:1 ratio to receive the low dose (apitegromab 2 mg /kg Q4W) or high dose (apitegromab 20 mg/kg Q4W); both treatment arms were in
                conjunction with an approved SMN upregulator therapy (nusinersen). </font></strong>Three patients (two in high-dose arm and one in low-dose arm) each missed three consecutive doses of apitegromab due to COVID-19-related site access
            restrictions and were excluded from the prespecified intent-to-treat primary analysis. The primary objectives of the cohort were to assess safety and the mean change from baseline in HFMSE following 12 months of treatment. </p>
          <p> <strong><font style="text-align: center; list-style-position: inside;font-weight:normal;">Cohort 3 efficacy data demonstrate further improvements in motor function relative to what was observed at the six-month interim analysis. The mean
                change from baseline in HFMSE score was a 7.1-point and a 5.3-point improvement for the 20 mg/kg and 2 mg/kg dose arms, respectively. The majority (59%) of patients in Cohort 3 achieved at least a 5-point increase in HFMSE and 35% of
                patients achieved greater than a 10-point increase in HFMSE over baseline. </font></strong> </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> Dose response was observed; the 20 mg/kg dose achieved numerically greater mean improvements from baseline in HFMSE scores than the 2 mg/kg dose across all assessed timepoints in the 12-month treatment period. The clinically observed dose
            response was consistent with the pharmacodynamic (target engagement) results. Both the 20 mg/kg and 2 mg/kg doses yielded high levels of target engagement (&gt;100-fold increase from baseline), but the 20 mg/kg dose led to a relatively higher
            absolute level of target engagement. </p>
          <table cellspacing="0" id="z867bfbdebbeb43baa5e4a6f94290b20e" style="margin-bottom: 10px;margin-left: 0px; margin-right: auto; font-size: 10pt;">

              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> <b>Cohort 3 <br>
                    </b>(Intent-to-treat population) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>Apitegromab 20 mg/kg <br>
                      + nusinersen (n=8)</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>Apitegromab 2 mg/kg <br>
                      + nusinersen (n=9)</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>Apitegromab pooled <br>
                      (n=17)</b> </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> Mean change from baseline in HFMSE score (95% CI) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> +7.1 (+1.8, +12.5) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> +5.3 (-1.5, +12.2) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> +6.2 (+2.2, +10.1) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> % of patients attaining &#8805;1-point increase in HFMSE score </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 7/8 (88%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 7/9 (78%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 14/17 (82%) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> % of patients attaining &#8805;3-point increase in HFMSE score </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 5/8 (63%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 5/9 (56%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 10/17 (59%) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> % of patients attaining &#8805;5-point increase in HFMSE score </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 5/8 (63%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 5/9 (56%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 10/17 (59%) </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> % of patients attaining &gt;10-point increase in HFMSE score </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 3/8 (38%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 3/9 (33%) </p>
                </td>
                <td colspan="1" rowspan="1" style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: center; list-style-position: inside;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: center; list-style-position: inside;"> 6/17 (35%) </p>
                </td>
              </tr>

          </table>
          <p> <b>Overall safety and tolerability profile: </b> </p>
          <ul style="list-style-type: disc;">
            <li> Incidence and severity of adverse events were consistent with the underlying patient population and background therapy. </li>
            <li> Five most frequently reported TEAEs: Headache (24%), pyrexia (22%), upper respiratory tract infection (22%), cough (22%), and nasopharyngitis (21%). </li>
            <li> Five patients experienced a serious treatment-emergent adverse event, all assessed by the respective trial investigator as unrelated to apitegromab:
              <ul style="list-style-type: circle;">
                <li> One patient treated with 2 mg/kg dose (Cohort 3) hospitalized due to adenoidal hypertrophy and tonsillar hypertrophy to perform scheduled adenotonsillectomy (Grade 2). Event resolved without sequelae. </li>
                <li> Two patients treated with 20 mg/kg dose (both Cohort 1) with gait inability considered a significant disability (both Grade 3). Events remain ongoing. </li>
                <li> One patient treated with 20 mg/kg dose (Cohort 1) hospitalized with post lumbar puncture syndrome (Grade 2). Event resolved without sequelae. </li>
                <li> One patient treated with 20 mg/kg dose (Cohort 1) hospitalized due to viral upper respiratory tract infection (Grade 2). Event resolved without sequelae. </li>
              </ul>
            </li>
            <li> One patient (Cohort 1) presented with a non-serious Grade 3 post lumbar puncture syndrome; assessed by trial investigator as unrelated to apitegromab. Event resolved without sequelae. </li>
            <li> One patient (Cohort 1) discontinued from the trial due to Grade 2 muscle fatigue that started prior to initiation of dosing with study drug; assessed by the trial investigator as unrelated to apitegromab. </li>
            <li> Anti-drug antibodies (ADA) were present at low titers following apitegromab treatment in three out of the 58 enrolled patients. No apparent impact on drug exposure was observed and was not associated with any hypersensitivity reactions. </li>
          </ul>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>Additional potential disease areas for apitegromab: </b>Scholar Rock believes apitegromab has potential for applicability across multiple SMA types, as well as in other neuromuscular indications. Based upon ongoing indication
            assessments, the Company has identified Becker Muscular Dystrophy (BMD), which affects approximately 20,000 individuals in the US and EU<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(a)</sup>, as the next potential indication for apitegromab. The Company is in the process of planning
            a proof-of-concept trial with an aim to initiate the trial in 2022. Scholar Rock is continuing to explore other myostatin-related indications for which fast-twitch fibers may play an important role in motor function. </p>
          <p> <b>Conference call/webcast: <br>
            </b>Scholar Rock will host a conference call and audio webcast to discuss the apitegromab TOPAZ Phase 2 clinical trial top-line results today at 8:00 a.m. Eastern Time. To participate in the call, please dial 833-519-1308 (domestic) or
            914-800-3874 (international) and refer to conference ID: 4196782. A webcast of the call will also be available on the Investors &amp; Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the
            webcast will be available on Scholar Rock&#8217;s website at: https://scholarrock.com/ for approximately 180 days following the presentation. </p>
          <p> (a) &#8220;Muscular Dystrophy: Disease Landscape and Forecast.&#8221; DRG Reports, June 2020 </p>
          <p> <b>About SMA <br>
            </b>Spinal muscular atrophy (SMA) is a rare, and often fatal, genetic disorder that typically manifests in young children. An estimated 30,000 to 35,000 patients are afflicted with SMA in the United States<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup> and Europe<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup>.
            It is characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness. The underlying pathology of SMA is caused by insufficient production of the SMN (survival of motor
            neuron) protein, essential for the survival of motor neurons, and is encoded by two genes, SMN1 and SMN2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup>. While there has been progress in the development of therapeutics that address the underlying SMA genetic defect, there
            continues to be a high unmet need for therapeutics that directly address muscle atrophy. </p>
          <p> (1) Lally, C. et al. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. Orphanet Journal of Rare Diseases. (2017) 12:175. <br>
            (2) Briefing Document to the Clinical Trial Readiness in Spinal Muscular Atrophy (SMA) SMA Europe, TREAT-NMD and European Medicines Agency meeting. Prepared by SMA Europe and TREAT-NMD. November 11, 2016. <br>
            (3) Parente, V. and Corti, S. Advances in spinal muscular atrophy therapeutics. Therapeutic Advances in Neurological Disorders. (2018) 11:1. </p>
          <p> <b>About Apitegromab <br>
            </b>Apitegromab (SRK-015) is a selective inhibitor of the activation of latent myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA). Myostatin, a member of the TGF&#946; superfamily
            of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species. Scholar Rock believes the inhibition of the activation of
            latent myostatin with apitegromab may promote a clinically meaningful improvement in motor function. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> The TOPAZ Phase 2 clinical trial in patients with Type 2 and Type 3 SMA is ongoing in the extension phase (NCT03921528). The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD)
            designation, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) Designation and Orphan Medicinal Product Designation, to apitegromab for the treatment of SMA. The efficacy and safety of apitegromab have not been
            established and apitegromab has not been approved for any use by the FDA or any other regulatory agency. </p>
          <p> <b>About Scholar Rock <br>
            </b>Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar
            Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock&#8217;s
            approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at
            the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its
            focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit https://scholarrock.com/ or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn
            (https://www.linkedin.com/company/scholar-rock/). </p>
          <p> Scholar Rock<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a registered trademark of Scholar Rock, Inc. </p>
          <p> <b>Forward-Looking Statements <br>
            </b>This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the potential of apitegromab, Scholar Rock&#8217;s future
            expectations, plans and prospects, including without limitation, Scholar Rock&#8217;s expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab, the potential of its proprietary platform, and its
            intellectual property protection.<i> </i>The use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions
            are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results
            to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the possibility that preclinical and clinical data, including the 12-month top-line results from the
            Phase 2 trial of apitegromab, are not predictive of, are inconsistent with, or more favorable than, data generated from future clinical trials of the same product candidate, including the planned Phase 3 registrational trial of apitegromab in
            SMA, Scholar Rock&#8217;s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock&#8217;s nonclinical and preclinical studies and
            clinical trials, information provided or decisions made by regulatory authorities, competition from third parties that are developing products for similar uses, Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property,
            Scholar Rock&#8217;s dependence on third parties for development and manufacture of product candidates including to supply any clinical trials, Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its
            business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts of public health pandemics such as COVID-19 on business operations including its clinical trials, as well as those risks
            more fully discussed in the section entitled "Risk Factors" in Scholar Rock&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in Scholar
            Rock&#8217;s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. All
            information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b>Scholar Rock: </b><br>
            <b>Investors: </b><br>
            Catherine Hu <br>
            chu@scholarrock.com </p>
          <p> <b>Media: </b><br>
            Ariane Lovell <br>
            Finn Partners <br>
            ariane.lovell@finnpartners.com<br>
            917-565-2204 </p>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
<div><a name="a52406941ex99_2.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.2</font><br>
  </div>
  <div> <br>
  </div>
  <div style="text-align: center;">
    <title></title>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide1.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;TOPAZ Phase 2 Trial Top-Line Results&#160;&#160;April 6, 2021&#160;&#160;Improvements in Motor Function with Apitegromab for
            Patients with Spinal Muscular Atrophy (SMA)&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide2.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Disclaimers&#160;&#160;Various statements in this presentation concerning the future expectations, plans and
            prospects of Scholar Rock, Inc. (&#8220;Scholar Rock&#8221;), including without limitation, Scholar Rock&#8217;s expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting
            results from its clinical trials for its product candidates, its disease indication selection and timing for such selection, the ability of apitegromab to affect the treatment of patients suffering from Spinal Muscular Atrophy (SMA) either as a
            monotherapy or in conjunction with the current standard of care, and the ability of SRK-181 to affect the treatment of cancer patients constitute forward-looking statements for the purposes of the safe harbor provisions under The Private
            Securities Litigation Reform Act of 1995. The use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar
            expressions are intended to identify such forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Scholar
            Rock&#8217;s ability to provide the financial support and resources necessary to identify and develop multiple product candidates on the expected timelines, competition from others developing products for similar uses, the preliminary nature of
            interim clinical data, the possibility that preclinical or clinical data is inconsistent with subsequent data, Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property, Scholar Rock&#8217;s dependence on third parties for
            development and manufacture of product candidates including to supply any clinical trials, and Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain
            strategic business alliances and new business initiatives as well as those risks more fully discussed in the section entitled "Risk Factors" in the Annual Report on Form 10-K for the year ended&#160;December 31, 2020, which is on file with
            the&#160;Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements
            represent Scholar Rock&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. Scholar Rock explicitly disclaims any obligation to update any forward-looking statements unless required by law.
            &#160;&#160;&#169; Scholar Rock, Inc. All rights reserved. April 2021. &#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide3.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Agenda&#160;&#160;3&#160;&#160;Opening Remarks &#160;&#160;Next Steps for Apitegromab Program&#160;&#160;Tony Kingsley, President &amp; CEO&#160;&#160;Tony
            Kingsley, President &amp; CEOTed Myles, Chief Financial Officer&#160;&#160;&#160;&#160;Questions and Answers&#160;&#160;Trial Design and Baseline Characteristics&#160;&#160;Top-line Safety and Efficacy Results&#160;&#160;Yung Chyung M.D., Chief Medical Officer&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide4.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;4&#160;&#160;Bringing a Revolutionary Approach to Highly Sought-After Growth Factors Implicated in Devastating
            Diseases&#160;&#160;&#160;&#160;Scholar Rock&#8217;s Target&#160;&#160;Growth Factor Precursor (Latent Form)&#160;&#160;Scholar Rock&#8217;s R&amp;D PlatformTransform Medical Practice&#160;&#160;Pursue important targets with well-validated biology but are difficult to drugApply revolutionary approach to
            tough targetsLeverage deep insights into structure and function Engineer antibodies to deliver differentiated therapeutic profiles(i.e. exquisite selectivity)&#160;&#160;TOPAZ demonstrates the therapeutic potential of inhibiting the latent forms of
            growth factors&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide5.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Apitegromab Offers Potential to Pioneer a New Treatment Era to Improve Motor Function in Patients with
            SMA&#160;&#160;5&#160;&#160;SMN = survival motor neuron. *Also referred to as SMN correctors. **Apitegromab (SRK-015) is an investigational product candidate under development.&#160;&#160;SMN Upregulator Therapies* + Muscle-Directed Therapy (apitegromab) Potential for
            Enhanced Outcomes for Patients&#160;&#160;Apitegromab (SRK-015)**&#160;&#160;SMN Upregulator TherapiesAddress SMN deficiency to prevent further motor neuron deterioration &#160;&#160;Muscle-Directed TherapiesAct directly on muscle with aim to improve motor function &#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide6.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;6&#160;&#160;TOPAZ 12-Month Data Further Support the Potential of Apitegromab in Patients with Type 2 and Type 3
            SMA&#160;&#160;&#8226;Cohort 2: Mean change in HFMSE score from baseline was updated to +1.1-points (from +1.4-points). Proportion of patients with &#8805;3-point increases was updated to 2/14 (from 3/14) and updated to 1/14 (from 2/14) for patients with &#8805;5-point
            increases.&#8226;Cohort 3 high dose arm (20 mg/kg): Mean change in HFMSE score from baseline was revised to +5.3-points (from +5.6-points).&#160;&#160;Mean RHS decline from baselineMajority of patients maintained or improved (&#8805;0-pt change from baseline)&#160;&#160;TOPAZ
            6-month interim results*&#160;&#160;TOPAZ 12-month top-line results&#160;&#160;Mean RHS increase from baselineMajority of patients maintained or improved (&#8805;0-pt change from baseline)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mean HFMSE increase from baseline Majority of patients improved (&#8805;1-pt
            increase from baseline)Sizeable % of patients achieved &#8805;3-pt increase (29%)&#160;&#160;Mean HFMSE increase from baselineMajority of patients improved (&#8805;1-pt increase from baseline)&#160;&#160;Further HFMSE increases observed vs. 6-month interim analysisMajority of
            patients achieved &#8805;5-pt increaseDose response continues to be observed&#160;&#160;Mean HFMSE increases from baselineMajority of patients achieved &#8805;3-pt increaseDose response observed&#160;&#160;Adverse events were consistent with the underlying patient population
            and background therapy &#160;&#160;Cohort 1Ambulatory Type 3&#160;&#160;Cohort 2Type 2 &amp; non-ambulatory Type 3 (initiated nusinersen &#8805;5 yrs)&#160;&#160;Cohort 3Type 2(initiated nusinersen &lt;5 yrs)&#160;&#160;*Database for HFMSE and RHS scores for the 12-month topline analysis
            are locked. The 6-month interim analysis was a snapshot and subsequent adjustments by sites investigators resulted in the following changes to the 6-month interim results:&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide7.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Phase 2 Trial Design and 12-Month Top-Line Results&#160;&#160;Yung Chyung, M.D. Chief Medical Officer&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide8.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Apitegromab Phase 2 Trial Design&#160;&#160;Design&#160;&#160;Patients&#160;&#160;Primary Objectives&#160;&#160;HFMSE=Hammersmith Functional
            Motor Scale Expanded; RHS=Revised Hammersmith ScaleData on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160;Evaluate potential of apitegromab in improving motor function in patients with Type 2 and Type 3 SMA&#160;&#160;8&#160;&#160;&#160;&#160;Ambulatory Patients(Revised
            Hammersmith Scale)&#160;&#160;Non-Ambulatory Patients(Hammersmith Functional Motor Scale Expanded)&#160;&#160;&#160;&#160;Cohort 1&#160;&#160;Cohort 2&#160;&#160;Cohort 3&#160;&#160;N= 23; ages 5-21Open-label, single-arm20 mg/kg apitegromab IV Q4W12-month treatment period &#160;&#160;N= 15; ages 5-21 Open-label,
            single-arm20 mg/kg apitegromab IV Q4W12-month treatment period&#160;&#160;N= 20; ages &#8805;2Double-blind, randomized (1:1) to 2 mg/kg or 20 mg/kg apitegromab IV Q4W12-month treatment period&#160;&#160;Ambulatory Type 3 SMATwo subgroups: Receiving background nusinersen
            Apitegromab monotherapy&#160;&#160;Type 2 or non-ambulatory Type 3 SMAReceiving background nusinersen (initiated &#8805;5 years of age)&#160;&#160;Type 2 SMA Receiving background nusinersen (initiated before 5 years of age)&#160;&#160;SafetyMean change from baseline in
            RHS&#160;&#160;SafetyMean change from baseline in HFMSE&#160;&#160;SafetyMean change from baseline in HFMSE&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide9.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Considerations in the Conduct and Design of TOPAZ Proof-of-Concept Study&#160;&#160;9&#160;&#160;Main focus of TOPAZ was to
            assess the potential additive therapeutic benefit of apitegromab on top of background SMN upregulator therapy.*While the protocol allowed the use of any approved SMN upregulator as background therapy, only nusinersen had widespread use during
            TOPAZ trial enrollment. Specifically designed with 3 distinct cohorts to assess apitegromab&#8217;s potential across patient populations with varying disease severity and different background expectations for disease course.Clinical data for
            nusinersen and natural history data help inform our background expectations for disease course for the different populations evaluated in TOPAZ.These insights further our understanding as we continue to investigate apitegromab in SMA.Cohort 3
            evaluated two dose arms as we recognized that complete target saturation may not be necessary to achieve therapeutic effect.Low dose of 2 mg/kg was selected to explore this question by aiming for a high level of target engagement but lower than
            that of the 20 mg/kg dose.&#160;&#160;*An apitegromab monotherapy subgroup was included in Cohort 1.&#160;&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide10.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Baseline Characteristics&#160;&#160;10&#160;&#160;&#160;&#160;Ambulatory Patients&#160;&#160;&#160;&#160;&#160;&#160;Non-Ambulatory Patients&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cohort
            1&#160;&#160;&#160;&#160;&#160;&#160;Cohort 2&#160;&#160;Cohort 3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20 mg/kgmonotherapy&#160;&#160;20 mg/kg +nusinersen&#160;&#160;Pooled&#160;&#160;20 mg/kg +nusinersen&#160;&#160;20 mg/kg +nusinersen&#160;&#160;2 mg/kg +nusinersen&#160;&#160;Pooled&#160;&#160;N &#160;&#160;11&#160;&#160;12&#160;&#160;23&#160;&#160;15&#160;&#160;10&#160;&#160;10&#160;&#160;20&#160;&#160;Mean age (min, max)&#160;&#160;12.1 (7, 19)&#160;&#160;13.1 (7, 21)&#160;&#160;12.6
            (7, 21)&#160;&#160;11.7 (8, 19)&#160;&#160;3.8 (2, 6)&#160;&#160;4.1 (2, 6)&#160;&#160;4.0 (2, 6)&#160;&#160;Female (%)&#160;&#160;73%&#160;&#160;58%&#160;&#160;65%&#160;&#160;53%&#160;&#160;50%&#160;&#160;30%&#160;&#160;40%&#160;&#160;SMN2 Gene Copy* (#, %)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2&#160;&#160;1 (9%)&#160;&#160;0 (0%)&#160;&#160;1 (4%)&#160;&#160;&#160;&#160;1 (10%)&#160;&#160;1 (10%)&#160;&#160;2 (10%)&#160;&#160;3&#160;&#160;4 (36%)&#160;&#160;9 (75%)&#160;&#160;13 (57%)&#160;&#160;11 (73%)&#160;&#160;8
            (80%)&#160;&#160;8 (80%)&#160;&#160;16 (80%)&#160;&#160;4&#160;&#160;4 (36%)&#160;&#160;1 (8%)&#160;&#160;5 (22%)&#160;&#160;2 (13%)&#160;&#160;0 (0%)&#160;&#160;1 (10%)&#160;&#160;1 (5%)&#160;&#160;Mean # of nusinersen maintenance doses (min, max)&#160;&#160;N/A&#160;&#160;5.6 (2, 8)&#160;&#160;N/A&#160;&#160;5.1 (2, 9)&#160;&#160;5.4 (3, 8)&#160;&#160;5.5 (2, 9)&#160;&#160;5.5 (2,
            9)&#160;&#160;Discontinuation(s)&#160;&#160;0&#160;&#160;1**&#160;&#160;1**&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;Mean RHS score (min, max)&#160;&#160;47.6 (26, 63)&#160;&#160;51.3 (43, 62)&#160;&#160;49.6 (26, 63)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mean HFMSE score (min, max)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;22.7 (13, 39)&#160;&#160;23.5 (14, 42)&#160;&#160;26.1 (12, 44)&#160;&#160;24.8 (12, 44)&#160;&#160;*Data not available
            for all patients**Patient who discontinued study for reasons unrelated to study drugHFMSE=Hammersmith Functional Motor Scale Expanded; RHS=Revised Hammersmith Scale&#160;&#160;Data on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160;&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide11.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Safety Results from TOPAZ 12-Month Top-Line Analysis Support Evaluation of Apitegromab in Phase 3
            Trial&#160;&#160;11&#160;&#160;Treatment-emergent adverse events (TEAEs)&#160;&#160;Apitegromab 2 mg/kg (n=10)&#160;&#160;Apitegromab 20 mg/kg (n=48)&#160;&#160;Total(n=58)&#160;&#160;Any TEAE&#160;&#160;9 (90.0%)&#160;&#160;44 (91.7%)&#160;&#160;53 (91.4%)&#160;&#160;Any Serious TEAE&#160;&#160;1 (10.0%)&#160;&#160;4 (8.3%)&#160;&#160;5 (8.6%)&#160;&#160;Any TEAE leading to study
            drug discontinuation&#160;&#160;0 (0.0%)&#160;&#160;1 (2.1%)&#160;&#160;1 (1.7%)&#160;&#160;Any Grade 3 (severe) or higher TEAE&#160;&#160;0 (0.0%)&#160;&#160;3 (6.2%)&#160;&#160;3 (5.2%)&#160;&#160;Treatment-emergent adverse events (TEAEs) are defined as AEs that start after the first dose of study drug or start prior to
            the administration of study drug and worsen in severity/grade or relationship to investigational medication after the administration of study drug.*TEAE rates are across all patients in TOPAZ trialData on file. Scholar Rock, Inc. Cambridge,
            MA&#160;&#160;Five most frequently reported TEAEs*:&#160;Headache (24%), pyrexia (22%), upper respiratory tract infection (22%), cough (22%), and nasopharyngitis (21%).&#8203;Anti-drug antibodies (ADA) were present at low titers following apitegromab treatment in 3
            out of 58 enrolled patients. No apparent impact on drug exposure was observed and was not associated with any hypersensitivity reactions. No safety signals identified as of the TOPAZ 12-month top-line analysis&#160;&#160;Incidence and severity of AEs
            were consistent with the underlying patient population and background therapy&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide12.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Serious and Severe Treatment-Emergent Adverse Events (TEAEs)&#160;&#160;12&#160;&#160;Treatment-emergent adverse events
            (TEAEs) are defined as AEs that start after the first dose of study drug or start prior to the administration of study drug and worsen in severity/grade or relationship to investigational medication after the administration of study drug.Data
            on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160;&#160;&#160;2 mg/kg: &#160;&#8203;Cohort 3: 1 patient hospitalized due to adenoidal and tonsillar hypertrophy and scheduled adenotonsillectomy (Grade 2). Resolved without sequelae.&#8203;20 mg/kg:&#8203;Cohort 1: 2 patients with gait
            inability considered a&#160;significant disability (both Grade 3). Events&#160;remain ongoing.&#160;&#8203;Cohort 1: 1 patient&#160;hospitalized with post lumbar puncture syndrome (Grade 2). Resolved without sequelae.&#8203;Cohort 1: 1 patient hospitalized due to viral upper
            respiratory infection (Grade 2/prior history). Resolved without sequelae.&#8203;&#160;&#160;Serious TEAEs; All Assessed by Trial Investigators as Unrelated to Apitegromab&#160;&#160;Other&#160;Severe TEAE; Assessed by Trial Investigator as Unrelated to Apitegromab &#160;&#8203;&#160;&#160;Study
            Discontinuation; Assessed by Trial Investigator as Unrelated to Apitegromab&#160;&#160;Cohort 1: 1 patient presented with post lumbar&#160;puncture syndrome (non-serious Grade 3). Resolved without sequelae.&#8203;&#160;&#160;Cohort 1: 1 patient withdrew consent after ~2
            months in the trial. Grade 2 leg&#160;muscle fatigue (developed prior to enrollment). &#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide13.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;13&#160;&#160;Cohort 1 data suggest potential clinical effect in certain patients in this patient populationMean
            decline in RHS from baselineMajority (57%) maintained or improved in RHS (&#8805;0-point change from baseline) and 22% achieved &#8805;3-point increaseCohort 2 observed improvement of motor function from baselineMean improvement in HFMSE from baseline;
            potential durability of improvement apparent up to 12-monthsMajority (64%) achieved &#8805;1-point increase in HFMSE and sizeable subset (29%) achieved &#8805;3-point increaseCohort 3 observed further improvements in motor function and continued dose
            response vs. 6-month interim analysisLarge mean improvement in HFMSE from baseline in both dose arms; high dose numerically outperformed low doseMajority (59%) achieved &#8805;5-point increase and sizeable subset (35%) achieved &gt;10-point increase
            in HFMSE &#160;&#160;TOPAZ 12-Month Top-line Results Demonstrate Potential of Apitegromab for Patients with Type 2 and Type 3 SMA&#160;&#160;&#160;&#160;Ambulatory Patients(Revised Hammersmith Scale)&#160;&#160;&#160;&#160;&#160;&#160;Non-Ambulatory Patients(Hammersmith Functional Motor Scale
            Expanded)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Intent-to-Treat Population)&#160;&#160;Cohort 1&#160;&#160;&#160;&#160;&#160;&#160;Cohort 2*&#160;&#160;Cohort 3*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20 mg/kgmonotherapy (n=11)&#160;&#160;20 mg/kg +nusinersen (n=12)&#160;&#160;Pooled(n=23)&#160;&#160;20 mg/kg +nusinersen (n=14)&#160;&#160;20 mg/kg +nusinersen(n=8)&#160;&#160;2 mg/kg
            +nusinersen(n=9)&#160;&#160;Pooled (n=17)&#160;&#160;Mean change from baseline (95% CI)&#160;&#160;-0.4 (-3.9, 3.1)&#160;&#160;-0.3 (-2.0, 1.4)&#160;&#160;-0.3 (-2.1, 1.4)&#160;&#160;+0.6 (-1.4, 2.7)&#160;&#160;+7.1 (1.8, 12.5)&#160;&#160;+5.3 (-1.5, 12.2)&#160;&#160;+6.2 (2.2, 10.1)&#160;&#160;# (%) pts achieving &#8805;1-pt increase&#160;&#160;4/11
            (36%)&#160;&#160;5/12 (42%)&#160;&#160;9/23 (39%)&#160;&#160;9/14 (64%)&#160;&#160;7/8 (88%)&#160;&#160;7/9 (78%)&#160;&#160;14/17 (82%)&#160;&#160;# (%) pts achieving &#8805;3-pt increase&#160;&#160;3/11 (27%)&#160;&#160;2/12 (17%)&#160;&#160;5/23 (22%)&#160;&#160;4/14 (29%)&#160;&#160;5/8 (63%)&#160;&#160;5/9 (56%)&#160;&#160;10/17 (59%)&#160;&#160;*4 patients (1 in Cohort 2 and 3 in Cohort 3)
            each missed 3 doses of apitegromab due to COVID-19-related site access restrictions and were not included in the primary (intent-to-treat) analysis. Data on file. Scholar Rock, Inc. Cambridge, MA&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide14.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Cohort 1&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide15.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Background Insights into Ambulatory Type 3 SMA Patients&#160;&#160;Source: Coratti, et, al. Annals of Neurology
            (2020; 88:1109-1117) DOI: 10.1002/ana.25900This third-party information is provided for background only and is not intended to convey or imply a comparison to the TOPAZ clinical trial results.&#160;&#160;15&#160;&#160;Coratti et, al. Natural History Study of
            Ambulatory Type 3 SMA&#160;&#160;Motor function decline is common in ambulatory Type 3 SMA and can be severe in a subset of patients&#160;&#160;&#160;&#160;12-month assessmentsMean change in HFMSE from baseline was -0.79 points&#8203;11 patients lost ambulation - mean age at
            ambulation loss was 10.21 years (SD&#177;6.43) &#160;&#160;Baseline characteristics130 patients with ambulatory Type 3 SMA (some patients were lost to follow-up over time)&#8203;Mean age at baseline of 10.05 Mean HFMSE score of 52.81&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide16.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;Cohort 1: Mean Decline in RHS at 12-Months but Majority of Patients Maintained or Improved in RHS
            Score from Baseline&#160;&#160;16&#160;&#160;Individual RHS responses&#160;&#160;Ambulatory Type 3 SMA (Intent-to-Treat Population)&#160;&#160;Apitegromab (20 mg/kg)monotherapy (n=11)&#160;&#160;Apitegromab (20 mg/kg) + nusinersen (n=12)&#160;&#160;Pooled (n=23)&#160;&#160;Mean change from baseline in RHS (95%
            CI)&#160;&#160;-0.4 (-3.9, 3.1)&#160;&#160;-0.3 (-2.0, 1.4)&#160;&#160;-0.3 (-2.1, 1.4)&#160;&#160;# (%) patients achieving &#8805;1-pt increase in RHS&#160;&#160;4/11 (36%)&#160;&#160;5/12 (42%)&#160;&#160;9/23 (39%)&#160;&#160;# (%) patients achieving &#8805;3-pt increase in RHS&#160;&#160;3/11 (27%)&#160;&#160;2/12 (17%)&#160;&#160;5/23 (22%)&#160;&#160;# (%) patients
            achieving &#8805;5-pt increase in RHS&#160;&#160;1/11 (9%)&#160;&#160;0/12 (0%)&#160;&#160;1/23 (4%)&#160;&#160;Mean (&#177;SEM) change from baseline in RHS scores &#160;&#160;*Includes 2 patients in monotherapy and 2 patients in apitegromab + nusinersen subgroup who maintained RHS score (0-point change
            from baseline)Per protocol and sensitivity (all patients) analyses showed similar results to primary intent-to-treat analysisapitegromab = SRK-015 Data on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160;&#160;&#160;13/23* (57%) maintained or improved in RHS
            (&#8805;0-point change from baseline) &#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide17.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Cohort 2&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide18.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;18&#160;&#160;Nusinersen CHERISH Trial in Later-Onset SMA (15-month treatment period)&#160;&#160;*Mercuri E, et.al.
            Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625-635.**Mercuri E. et al. Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials.
            https://doi.org/10.1016/j.nmd.2015.10.006This third-party information is provided for background only and is not intended to convey or imply a comparison to the TOPAZ clinical trial results.&#160;&#160;CHERISH&#8203; clinical trial data*After 15 months of
            treatment in patients who started on&#160;nusinersen&#160;at age&#160;&gt;5....&#8203;Mean HFMSE decline of &gt;0.5-points&#8203;&lt;15% with&#160;&#8805;3-point increase&#8203;&#8203;Natural history study**After 12-month follow-up in patients age&#160;&gt;5...&#8203;Mean HFMSE decline &#8203;&lt;5%
            with&#160;&#8805;3-point increase&#8203;&#160;&#160;Majority of patients in this age range do not experience HFMSE improvements and rarely achieve a &#8805;3-point increase&#160;&#160;Background Insights Into Non-Ambulatory Later-Onset SMA &#8805;5 Years of Age&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide19.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Cohort 2: Improvement in Mean HFMSE at 12-Months with Majority of Patients Achieving &#8805;1-point
            Increase&#160;&#160;Individual HFMSE responses&#160;&#160;Type 2 and Non-Ambulatory Type 3 SMA&#160;&#160;Apitegromab (20 mg/kg) + nusinersen&#160;&#160;&#160;&#160;&#160;&#160;Intent-to-Treat Population (n=14)&#160;&#160;Per Protocol Population* (n=13)&#160;&#160;Mean change from baseline in HFMSE (95% CI)&#160;&#160;+0.6 (-1.4,
            2.7)&#160;&#160;+1.2 (-0.5, 2.9)&#160;&#160;# (%) patients achieving &#8805;1-pt increase in HFMSE&#160;&#160;9/14 (64%)&#160;&#160;9/13 (69%)&#160;&#160;# (%) patients achieving &#8805;3-pt increase in HFMSE&#160;&#160;4/14 (29%)&#160;&#160;4/13 (31%)&#160;&#160;# (%) patients achieving &#8805;5-pt increase in HFMSE&#160;&#160;2/14 (14%)&#160;&#160;2/13
            (15%)&#160;&#160;19&#160;&#160;Mean (&#177;SEM) change from baseline in HFMSE scores &#160;&#160;&#160;&#160;*Patient had concomitant exposure to an acetylcholinesterase inhibitor, which is not permitted per the TOPAZ trial protocol Sensitivity analysis (all patients) showed similar
            results to primary intent-to-treat analysisapitegromab = SRK-015. Data on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160;&#160;&#160;Per protocol analysis* excludes patient (-7 pts). &#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide20.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Cohort 3&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide21.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Background Insights Into Non-Ambulatory Later-Onset SMA with Early Initiation of Nusinersen
            Therapy&#160;&#160;21&#160;&#160;Nusinersen SHINE Trial in Later-Onset SMA*&#160;&#160;Source: Darras, B., et.al. Nusinersen in later-onset spinal muscular atrophy. Neurology. May 2019; 92 (21) e2492-e2506.&#8220;Longer-term treatment with nusinersen: results in later-onset
            spinal muscular atrophy from the SHINE study&#8221; P.257, World Muscle Society Congress 2020This third-party information is provided for background only and is not intended to convey or imply a comparison to the TOPAZ clinical trial results.&#160;&#160;*Most
            nusinersen-treated patients in CHERISH were under age 5 years at time of therapy initiation&#160;&#160;TOPAZ Cohort 3Patients on average had received ~2 years of treatment with nusinersen at baseline and ~3 years by the 12-month analysis
            timepoint.&#160;&#160;Nusinersen SHINE TrialSHINE data suggest nusinersen-treated patients primarily stabilize or experience modest and gradual improvement beyond the initial 15 months of therapy&#160;&#160;Mean (+ SE) Change in HFMSETotal Score From Baseline&#160;&#160;1
            92 169 253 350 450 690 930 1170 1410 1650&#160;&#160;Analysis Visit, d&#160;&#160;n = 84 82 84 84 83 76 83 83 79 61 20&#160;&#160;n = 42 40 18 24 37 35&#160;&#160;n = 42 41 41 41 42 39&#160;&#160;-1-2-3-4&#160;&#160;8765&#160;&#160;43210&#160;&#160;Nusinersen in CHERISH and SHINENusinersen in SHINE (sham control in
            CHERISH)Sham control in CHERISH&#160;&#160;4.6&#160;&#160;1.7&#160;&#160;-0.4&#160;&#160;&#160;&#160;&#160;&#160;Long-term follow-up of nusinersen therapy&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide22.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Cohort 3: Sizeable Continued Improvements in Mean HFMSE Observed Across 12 Months&#160;&#160;22&#160;&#160;Individual HFMSE
            responses&#160;&#160;Type 2 SMA (Intent-to-Treat Population)&#160;&#160;Apitegromab 20 mg/kg + nusinersen (n=8)&#160;&#160;Apitegromab 2 mg/kg + nusinersen (n=9)&#160;&#160;Pooled (n=17)&#160;&#160;Mean change from baseline in HFMSE (95% CI)&#160;&#160;+7.1 (1.8, 12.5)&#160;&#160;+5.3 (-1.5, 12.2)&#160;&#160;+6.2 (2.2,
            10.1)&#160;&#160;# (%) patients achieving &#8805;1-pt increase in HFMSE&#160;&#160;7/8 (88%)&#160;&#160;7/9 (78%)&#160;&#160;14/17 (82%)&#160;&#160;# (%) patients achieving &#8805;3-pt increase in HFMSE&#160;&#160;5/8 (63%)&#160;&#160;5/9 (56%)&#160;&#160;10/17 (59%)&#160;&#160;# (%) patients achieving &#8805;5-pt increase in HFMSE&#160;&#160;5/8 (63%)&#160;&#160;5/9
            (56%)&#160;&#160;10/17 (59%)&#160;&#160;Per protocol and sensitivity (all patients) analyses showed similar results to primary intent-to-treat analysis apitegromab = SRK-015 Data on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160; &#160;&#160;Mean (&#177;SEM) change from baseline in
            HFMSE scores &#160;&#160;6/17 (35%) with &gt;10-point increase in HFMSE&#160;&#160;&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide23.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Dose-proportional and sustained drug exposure following chronic administration of
            apitegromab&#160;&#160;Pharmacokinetic and Pharmacodynamic Data are Supportive of Clinically Observed Effects &#160;&#160;Both 2 mg/kg and 20 mg/kg doses yielded high levels of target engagement (&gt;100-fold increase from baseline)20 mg/kg dose offers relatively
            higher magnitude of target engagement than 2 mg/kg dose&#160;&#160;High levels of target engagement achieved by both doses, with relatively higher absolute levels with high dose&#160;&#160;23&#160;&#160;*Starting at day 28, measures are pre-dose trough levels&#160;&#160;Data on file.
            Scholar Rock, Inc. Cambridge, MA&#160;&#160;Pharmacokinetics* (PK)&#160;&#160;Pharmacodynamics (PD)&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide24.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;24&#160;&#160;12-Month Top-line Results Support the Therapeutic Potential of Apitegromab and Further
            Development&#160;&#160;Data on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160;&#160;&#160;57 Patients* Completed 12-Month TOPAZ Trial&#160;&#160;&#160;&#160;&#160;&#160;All Elected to Opt Into Extension Period&#160;&#160;*Excludes one patient from Cohort 1 that discontinued from the trial&#160;&#160;Cohort 1&#160;&#160;Mean RHS
            decline from baseline, but majority of patients maintained or improved (&#8805;0-pt change in RHS)Potential subset of patients with more pronounced effect (22% with &#8805;3-pt increase)&#8203;&#160;&#160;Cohort 2&#160;&#160;Mean HFMSE improvement from baseline Majority (64%) of
            patients improved (&#8805;1-pt increase in HFMSE) and sizeable subset (29%) attained &#8805;3-pt increase in HFMSE &#8203;&#160;&#160;Cohort 3&#160;&#160;Large HFMSE improvements from baseline, with dose response observed Majority (59%) of patients attained &#8805;5-pt increase and
            sizeable subset (35%) attained &gt;10-pt increase in HFMSE&#8203;PK/PD results support observed dose response&#8203;&#160;&#160;Safety&#160;&#160;No safety signals identified as of the 12-month top-line analysisIncidence and severity of AEs were consistent with the underlying
            patient population and background therapy &#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide25.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Hammersmith Functional Motor Scale Expanded for SMA (HFMSE)Total achievable score of 6633 distinct
            measures of an individual&#8217;s ability to perform various activitiesQuality and execution of each movement is ranked on a scale of 0, 1, 2&#160;&#160;&#160;&#160;http://columbiasma.org/docs/HFMSE_2019_Manual.pdf&#160;&#160;&#160;&#160;Plinth/chair sittingLong sittingOne hand to head in
            sittingTwo hands to head in sittingSupine to side-lyingRolls prone to supine over RRolls prone to supine over LRolls supine to prone over RRolls supine to prone over L Sitting to lyingProps on forearmsLifts head from proneProp on extended
            armsLying to sittingFour-point kneelingCrawlingLifts head from supineSupporting standingStand unsupportedSteppingRight hip flexion in supineLeft hip flexion in supineHigh kneeling to right half kneelHigh kneeling to left half kneelHigh kneeling
            to standing leading with left leg (through right half kneel)High kneeling to standing leading with right leg (through left half kneel)Stand to sitting on the floorSquatJump 12 inches forwardAscends 4 stairs with railing Descends 4 stairs with
            railingAscends 4 stairs without arm support Descends 4 stairs without arm support&#160;&#160;25&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide26.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;26&#160;&#160;Next Steps for Apitegromab Program Tony Kingsley - President &amp; CEOTed Myles - CFO &amp; Head of
            Business Ops&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide27.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;27&#160;&#160;Additional TOPAZ Data and Analyses Will Further Our Understanding of Apitegromab&#8217;s Potential in SMA
            &#160;&#160;Exploratory analyses, including patient-level dataAdditional outcome measuresAdditional safety data&#160;&#160;Plan to present 12-month top-line data and additional analyses at upcoming medical congresses&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide28.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;28&#160;&#160;Apitegromab Has Broad Potential in SMA&#8230;Global Disease with Overall Prevalence of 30,000-35,000 in
            U.S. and Europe Alone&#160;&#160;High unmet medical need; benefits of SMN upregulators not well establishedTOPAZ data suggest potential clinical benefit; possibly more pronounced in subset of patientsOpportunity for additional exploration of apitegromab,
            both as monotherapy and in conjunction with SMN upregulators&#160;&#160;Most prevalent population TOPAZ has shown potential to improve motor functionMany patients already treated with or eligible to be treated with SMN upregulators&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Highest
            incidence population and growing prevalence due to increased survivalTOPAZ Cohort 3 data points to potential benefit of treating at an early agePotential to evaluate apitegromab with all SMN upregulators, including gene therapy&#160;&#160;Ambulatory
            Patients with SMA&#160;&#160;Patients with Type 1 SMA&#160;&#160;Non-Ambulatory Patients with Type 2 and Type 3 SMA&#160;&#160;Subject to discussions with regulatory authorities; planned Phase 3 trial expected to initiate by
            year-end&#160;&#160;http://www.smafoundation.org/wp-content/uploads/2012/03/SMA-Overview.pdfhttps://www.curesma.org/wp-content/uploads/2018/01/SMA-VoP-for-publication-1-22-2018.pdf&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide29.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;29&#160;&#160;&#160;&#160;&#160;&#160;Spinal Muscular Atrophy&#160;&#160;Additional Indications&#160;&#160;Glucocorticoid induced myopathy&#160;&#160;Potential
            benefit for subset of patients unable to discontinue steroid therapy&#160;&#160;Post-cancer muscle recovery in pediatrics***&#160;&#160;Some children may develop severe muscle wasting from chemotherapy&#160;&#160;Late-onset Pompe Disease**&#160;&#160;Large percentage of patients
            treated with enzyme replacement therapies (ERTs)Existing ERTs may address underlying pathology, but muscle strength remains ongoing challenge&#160;&#160;Muscular Dystrophies&#160;&#160;&#8230;as well as Broad Potential Beyond SMA&#160;&#160;Becker Muscular Dystrophy*&#160;&#160;Prevalence
            of 15,000-25,000, substantially under-diagnosed in earliest stagesYounger population with less severe dystrophin deficiency and slower progressing muscle damage&#160;&#160;Non-AmbulatoryLater-Onset&#160;&#160;Type 1&#160;&#160;AmbulatoryLater-Onset&#160;&#160;Leverage TOPAZ findings
            to conduct further explorations in Type 1 and other subpopulations&#160;&#160;&#160;&#160;Duchenne Muscular Dystrophy*&#160;&#160;Other Dystrophies&#160;&#160;Potential for add-on muscle-directed therapy in other rare dystrophies with less severe phenotypes or upon availability of
            disease-stabilizing therapies&#160;&#160;Prevalence of 30,000-40,000 with very severe symptoms and high unmet needProgress in the development of next-generation disease-stabilizing therapies may enable add-on muscle-directed approach&#160;&#160;&#160;&#160;&#160;&#160;*&#8220;Muscular
            Dystrophy: Disease Landscape and Forecast.&#8221; DRG Reports, June 19, 2020**Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review, Journal of Neuology. 2013***A Systematic Review of Selected Musculoskeletal Late
            Effects in Survivors of Childhood Cancer, Current Pediatric Reviews. 2014&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide30.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;30&#160;&#160;Potential for Apitegromab in Becker Muscular Dystrophy (BMD); Aim to Initiate Clinical Trial in
            2022&#160;&#160;&#160;&#160;Strong fit for a selective inhibitor of latent myostatin&#8230;&#160;&#160;Key Scientific Question&#160;&#160;BMD Fit&#160;&#160;Genetic disorder present at birth, with majority of patients identified at young age (before 18)&#160;&#160;Is patient population young?&#160;&#160;Less severe
            dystrophin deficiency and muscle disease than DMD with slower progression&#160;&#160;Are muscles structurally intact?&#160;&#160;BMD causes a substantial deficit in fast-twitch muscle fibers&#160;&#160;Does disease impact fast-twitch fibers?&#160;&#160;Several endpoints(1) (NSAA,
            TTSTAND) dependent on fast-twitch fibers have been used in past pivotal studies of muscular dystrophy therapies &#160;&#160;Is there an established endpoint that relies on fast-twitch fibers?&#160;&#160;Source: KOL Interviews; Dystrophin levels and clinical
            severity in Becker muscular dystrophy patients, J Neurol Neurosurg Psychiatry. 2014; Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies, Scientific Reports, 2016&#160;&#160;(1)NSAA: North Star
            Ambulatory Assessment. TTSTAND: Time To Stand&#160;&#160;&#8230; with a sizeable unmet need to be addressed&#160;&#160;Estimated Prevalence of 15,000-25,000&#160;&#160;&#8804;18 Years of Age&#160;&#160;Adults&#160;&#160;Severe&#160;&#160;Moderate&#160;&#160;Mild&#160;&#160;&#160;Source: KOL Interviews; Practicing neurologist survey (N=21),
            &#8216;Muscular Dystrophy: Disease Landscape &amp; Forecast&#8217; published Jun 2020&#160;&#160;Natural adjacencies to current program in SMAPositions apitegromab program for evaluation in a range of other muscular dystrophies (e.g. Duchenne Muscular
            Dystrophy)&#160;&#160;&#160;&#160;~55%&#160;&#160;% of diagnosed population by age (estimated)&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide31.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Rare Pediatric Disease for SMA granted by FDAOrphan Drug Designation for SMA granted by FDA Priority
            Medicines (PRIME) Designation for SMA granted by EMAOrphan Medicinal Product Designation for SMA granted by EMA&#160;&#160;Broad Patent Portfolio Protecting Apitegromab Into Late 2030s; Multiple Designations Granted by FDA/EMA&#160;&#160;31&#160;&#160;Highlights of
            apitegromab patent portfolio:US 10,751,413 (2037): Composition of matter and methods of use for apitegromabUS 9,758,576 (2034): Composition of matter claims to mAbs that inhibit the activation of myostatin precursorUS 10,307,480 (2035):
            Antibodies that selectively inhibit myostatin activationUS 10,287,345 (2037): Treatment methods for various myostatin-related conditions US 10,946,036 (2037): Covers both add-on and combination therapy with a myostatin inhibitor and a neuronal
            corrector therapyUS 10,882,904 (2036): Broadly directed to use of apitegromab to achieve certain therapeutic effects; without limiting to specific indicationsUS 9,399,676 (2034): Methods of producing antibodies that bind pro/latent
            myostatin&#160;&#160;Multiple designations granted by FDA/EMA recognizing the potential for apitegromab to address unmet medical needs in SMA&#160;&#160;&#160;&#160;&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide32.jpg"></div>
      </div>
      <div style="text-align: center;" id="slideText">
        <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;Gilead fibrosis-focused TGF&#946; collaboration&#160;&#160;&#160;&#160;&#160;&#160;DRAGON Part A: dose escalation and continued
            follow-up&#160;&#160;ApitegromabSpinal Muscular Atrophy (SMA)&#160;&#160;SRK-181 Immuno-Oncology and Oncology&#160;&#160;Preclinical/ Platform&#160;&#160;TOPAZ 12M topline data&#160;&#160;Planned apitegromab Phase 3 program in SMA by year-end&#160;&#160;2021: Potential for Another Transformative
            Year&#160;&#160;&#160;&#160;&#160;&#160;TOPAZ extension&#160;&#160;Continue to discover and advance preclinical programs&#160;&#160;Multiple opportunities for additional myostatin-related indications beyond SMA and muscular dystrophies&#160;&#160;Multiple additional opportunities: 1) SRK-181 in
            oncology; 2) latent TGF&#946;1 immune cell in IO; 3) latent TGF&#946;1 immune cell in oncology&#160;&#160;Gilead Fibrosis collaboration&#160;&#160;&#160;&#160;2022 and Beyond&#160;&#160;2021&#160;&#160;Q3&#160;&#160;Q4&#160;&#160;Q2&#160;&#160;Latent TGF&#946;1 Immune Cell Immuno-Oncology and Oncology&#160;&#160;32&#160;&#160;&#160;&#160;&#160;&#160;DRAGON Part B to initiate
            mid-year: multiple tumor typesMelanomaNSCLCUrothelial CarcinomaOther Solid Tumor Types&#160;&#160;&#160;&#160;ApitegromabOther Indications&#160;&#160;Multiple opportunities in muscular dystrophies, including Becker Muscular Dystrophy&#160;</font></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
    </div>
    <div style="text-align: center;" id="slide">
      <div style="position: relative; left: 0px; top: 0px;" id="frame">
        <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/6169dff76714d3117372b799a64dabc1-a52406941ex99_2slide33.jpg"></div>
      </div>
    </div>
    <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
  </div>
</body>
</html>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/8151\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
